NCT02000453 - Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

August 8, 2014

Study Completion Date

August 8, 2014

Conditions

Colitis, Ulcerative

Interventions

DRUG

GSK2586184 400mg

White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.

Trial Locations (1)

1105 AZ

GSK Investigational Site, Amsterdam